Physician profile
Gilberto Rodriguez
NPI 1205833597
$5,073.36
in general payments reported to CMS, 2019-2025
19 companies · $811 in 2025
The $811 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $498 · 2021: $497 · 2022: $994 · 2023: $900 · 2024: $663 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.52 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Viiv Healthcare Company | $921.42 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $591.43 | 2019-2023 | Symtuza |
| Insmed, INC. | $546.09 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $439.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $415.51 | 2019-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Allergan, INC. | $282.90 | 2019-2020 | |
| Janssen Products, LP | $213.98 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $140.66 | 2020-2025 | Nuzyra |
| Shionogi INC | $128.63 | 2021-2023 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $53.79 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $43.07 | 2019-2020 | |
| Pfizer INC. | $41.63 | 2023-2025 | |
| Astellas Pharma US INC | $35.85 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $24.49 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.75 | 2022 | |
| Melinta Therapeutics, LLC | $20.70 | 2021 | |
| Aimmune Therapeutics, INC. | $19.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.